The comparison of clinical efficacy of SOX and XELOX in the neoadjuvant chemotherapy for advanced gastric carcinoma
10.11904/j.issn.1002-3070.2017.01.005
- VernacularTitle:SOX 和 XELOX 在进展期胃癌新辅助化疗中的临床疗效比较
- Author:
Li CHEN
;
Yuxin ZHANG
;
Yanjiao ZUO
;
Fei MA
;
Hongjiang SONG
;
Yingwei XUE
- Keywords:
Neoadjuvant chemotherapy;
Advanced gastric carcinoma;
Effective rate;
Disease free surviv-al;
Overall survival
- From:
Practical Oncology Journal
2017;31(1):23-30
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of SOX and XELOX in neoadjuvant chemo-therapy for advanced gastric carcinoma .Methods Seventy-five cases with advanced gastric carcinoma were se-lected from our hospital from Feb 1,2011 to Oct 1,2015.SOX and XELOX were used to these patients treatment . The relationship between SOX and XELOX with tumor stage ,clinical curative effect evaluation ,operation ,postop-erative pathology ,adverse reaction ,survival analysis with advanced gastric carcinoma had been analyzed retrospec -tively.Results The efficacy of SOX and XELOX were 47.22%,41.03%.Compared with the two groups ,the CT curative effect evaluation,effective rate,disease control rate had no significant differences (P>0.05).The median survival time of DFS and OS were significant between the two groups (P<0.05).Conclusion The SOX and XELOX for neoadjuvant chemotherapy of advanced gastric carcinoma treatment is safety and effective , and the XELOX is better than SOX in terms of long -term effect,prognosis and clinical benefits .
